Related references
Note: Only part of the references are listed.Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa
Abela Mpobela Agnarson et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis
S. D. Masuku et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2020)
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Zhiyi Lan et al.
LANCET RESPIRATORY MEDICINE (2020)
Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
Sedona Sweeney et al.
BMJ OPEN (2020)
The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case
Gesine Meyer-Rath et al.
PLOS ONE (2019)
Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging
Yang Li et al.
DRUG DEVELOPMENT RESEARCH (2019)
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China
Qianqian Fan et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis
Kathryn Schnippel et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2018)
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia
C. Hewison et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2018)
Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis
K. Schnippel et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2018)
Palliative Care in South Africa
Cornelia Drenth et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2018)
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad et al.
LANCET (2018)
Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis
Ana-Maria Ionescu et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2018)
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Norbert Ndjeka et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Experience of treatment Pre-XDR and XDR-TB/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia
Nana Kiria et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries
Xiaoyan Lu et al.
BMC HEALTH SERVICES RESEARCH (2017)
The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought
Thomas Wilkinson et al.
VALUE IN HEALTH (2016)
Steps of bedaquline implementation in Georgia
Nana Kiria et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany
Lara J. Wolfson et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa
E. Sinanovic et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2015)
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review
Yoko V. Laurence et al.
PHARMACOECONOMICS (2015)
Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
Lara J. Wolfson et al.
PLOS ONE (2015)
The Temporal Dynamics of Relapse and Reinfection Tuberculosis After Successful Treatment: A Retrospective Cohort Study
Florian M. Marx et al.
CLINICAL INFECTIOUS DISEASES (2014)
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study
Elize Pietersen et al.
LANCET (2014)
COSTS AND EFFECTIVENESS OF COMBINATION THERAPY WITH BEDAQUILINE AND OTHER ANTI-TUBERCULOSIS DRUGS IN PATIENTS WITH MULTI-AND EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS IN GERMANY
L. Wolfson et al.
VALUE IN HEALTH (2014)
COST EFFECTIVENESS OF BEDAQUILINE FOR THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
L. Wolfson et al.
VALUE IN HEALTH (2014)
Allowing for differential timing in cost analyses: discounting and annualization
D Walker et al.
HEALTH POLICY AND PLANNING (2002)
Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis
JF Rushby et al.
HEALTH POLICY AND PLANNING (2001)
Share Paper
